Research programme: brain disorder therapeutics - Lieber Institute for Brain Development
Latest Information Update: 04 Apr 2014
At a glance
- Originator Astellas Pharma; Eli Lilly; Lieber Institute for Brain Development; Lundbeck A/S; Pfizer; Roche
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Brain disorders; Schizophrenia
Most Recent Events
- 31 Mar 2014 Early research in Brain disorders and Schizophrenia in USA (unspecified route)